NCT01080651

Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole

Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part B)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: Male
• Age: 20 Years – 50 Years
• Healthy volunteers: Accepted

Summary

To evaluate the drug-drug interaction between rifampicin and voriconazole according to CYP2C19 genotype quantitatively following a single oral administration of 200 mg voriconazole

Conditions

• Invasive Aspergillosis

Interventions

Type	Name	Description
DRUG	Voriconazole	Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2010-03-04
• Last updated: 2011-08-19

Locations

1 site across 1 country: South Korea